We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA—OUTCOMES INDICATIVE FOR IMPROVED SURVIVAL OVERTIME.
- Authors
Bairey, O.; Lebel, E.; Buxbaum, C.; Porges, T.; Taliansky, A.; Gurion, R.; Goldschmidt, N.; Shina, T. Tzuk; Zektser, M.; Hofstetter, L.; Siegal, T.
- Abstract
A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA - OUTCOMES INDICATIVE FOR IMPROVED SURVIVAL OVERTIME Patients treated after 2012 received significantly more treatment with HD-MTX and rituximab, more consolidation treatments, and autologous stem cell transplantation. During this period, combination therapy became the treatment of choice, rituximab has been added to the induction therapy, and consolidation with irradiation was largely laid off and was mostly replaced by high-dose chemotherapy with or without autologous stem cell transplantation.
- Subjects
OVERTIME; LYMPHOMAS; STEM cell transplantation
- Publication
Hematological Oncology, 2023, Vol 41, p692
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3165_545